Preliminary data from two trials of Mirati Therapeutics, Inc.’s investigational KRAS G21C inhibitor adagrasib plus Merck & Co., Inc.’s PD-1 inhibitor Keytruda (pembrolizumab) in metastatic non-small cell lung cancer (mNSCLC) have disappointed observers, but the US firm is confident it can reach success in certain subgroups.
In the Phase II KRYSTAL-7 trial, adagrasib plus pembrolizumab attained a 49% objective response rate (ORR) in 53 clinically evaluable patients at a median follow-up of 3.5 months. In a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?